Company Overview and News
24 of 30 Dow Industrial Index stocks were tagged as "safer" for dividends because they showed positive one-year returns and free cash-flow yields greater than their dividend yields 9/20/18.
CAT WBA UTX DWDP WMT VZA JNJ CVX CSCO VZ INTC PFE MCD CSCOI
An upbeat economic scenario and strong growth in corporate earnings have encouraged investors to load up on U.S. stocks. The Dow Jones Industrial Average’s rise to an all-time high reflects the bullishness.
MASI QDEL BSX WBA ISRG UTX CVS MDT EOG
September 20, 2018: Markets opened higher again Thursday after which both the Dow and the S&P 500 indexes climbed to new all-time highs. Jobless claims fell last week to a level not seen in nearly 50 years and the Philadelphia Fed reported a near-doubling of its manufacturing index in September. Even tariff worries got buried. Energy was the only sector posting even a tiny loss Thursday as tech and consumer staples stocks were the day’s big gainers.
CATR CAT WBA INTC DWDP
Darden Restaurants – The parent of Olive Garden, Longhorn Steakhouse, and other restaurant chains earned $1.34 per share for its latest quarter, 10 cents a share above estimates. Revenue beat forecasts, as well. Darden's comparable-restaurant sales rose 3.3 percent, tripling consensus estimates, and it also raised its full-year outlook.
WFCNP RIO RIO RL WBA DRI SFIX RTPPF RTNTF DIS WFC GEC GE THO RHT RIO MLHR GNE
The past year has been tremendous for e-commerce giant Amazon (AMZN - Free Report) . The stock has gained a massive 96.8%, way ahead of the 15.8% rise of the S&P 500 Index. Online media giant Netflix (NFLX - Free Report) has surged 88.7%. Leading pizza delivery company, Domino’s Pizza (DPZ - Free Report) has risen 40.1% over the past year. On the contrary, retail drug store industry majors, Rite Aid (RAD - Free Report) and Walgreens Boots Alliance (WBA - Free Report) have witnessed a steep decline of 52.
HD TGT TXN RAD MDPEB WBA NFLX MDP
September 12, 2018: Markets opened mixed Wednesday and none of the major indexes strayed to far from the break-even line. Today brought the introduction of new hardware from Apple, an event about which more pixels are burned than perhaps any other. The Fed Beige Book also rolled out today with a lot of attention paid to energy. Consumer staples and energy are the day’s best performing staples while financial services and tech stocks lagged.
PG CATR CAT BOE WBA BA
Looking for a stock that has been consistently beating earnings estimates and might be well positioned to keep the streak alive in its next quarterly report? Walgreens Boots Alliance (NASDAQ:WBA), which belongs to the Zacks Retail – Pharmacies and Drug Stores industry, could be a great candidate to consider. After all, Walgreens stock has benefited from a nice streak of beating earnings estimates, especially when looking at the previous two reports.
Looking for a stock that has been consistently beating earnings estimates and might be well positioned to keep the streak alive in its next quarterly report? Walgreens Boots Alliance (WBA - Free Report) , which belongs to the Zacks Retail - Pharmacies and Drug Stores industry, could be a great candidate to consider.
Aetna (NYSE:AET) stock has soared of late, for two key reasons. First, a takeout of Aetna stock by CVS (NYSE:CVS) appears increasingly likely to pass regulatory muster. Secondly, CVS stock, a component of the consideration paid for AET stock, has gained, increasing the value of the offer.
FRED AMZN RAD WBA CVS AET
2018-09-18 - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...
2018-09-18 - Asif
Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...
2018-09-18 - Asif
Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...
Silicon Investor Message Boards
This table lists all message boards related to WBA / Walgreens Boots Alliance, Inc. on message board site Silicon Investor.
|Walgreen Boots Alliance - WBA||Walgreen Boots Alliance - WBA||Walgreen Boots Alliance - WBA||Snowball.com, Inc. (Nasdaq - SNOW)||Snowball.com, Inc. (Nasdaq - SNOW)||Snowball.com, Inc. (Nasdaq - SNOW)|
as of ET